Medicines Discovery Catapult
Prof. Chris Molloy has extensive work experience in various leadership roles within the healthcare and pharmaceutical industries. Prof. Chris served as the CEO of Medicines Discovery Catapult, where they led national collaborative R&D projects and promoted the adoption of new techniques and technologies. Prof. Chris also held the position of Non-Executive Chairman at NorthWest EHealth, Exploristics, and Thriva Health. Additionally, they served in key roles at the Department of Health and Social Care, including Chair of the National Industry Consortium for COVID-19 mass testing diagnostics and Founding National Director. Prior to these roles, they were the CEO of The RSA Group and held positions at RSA Executive Search, IDBS, and MerLion Pharmaceuticals.
Prof. Chris Molloy completed their Bachelor of Science (BSc) in Biomedical Sciences from the University of Bradford in 1990. Prof. Chris currently holds an Honorary Professorship in Cancer Sciences from The University of Manchester since 2019. In the same year, they also obtained a Postgraduate Diploma/Masters qualification in Company Direction from the Institute of Directors (IoD) and a Certificate in Company Direction from the same institution. Prior to their university education, they attended The Oratory School from 1981 to 1986.
This person is not in any offices
Medicines Discovery Catapult
We collaborate with UK medicines discovery and diagnostics organisations, giving them access to industry-leading expertise, cutting-edge technology, and high-quality data. We accelerate their progress, precision drugs get to clinical trials more rapidly, and patients get life-improving medicines earlier than they otherwise would have.